ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…Decision-making process for opicapone’s bedtime regimen
Objective: To clarify the decision-making process for opicapone’s bedtime regímen. Background: OPC, a new once-daily COMT inhibitor, was shown to be effective in the treatment…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)
Objective: The PD MED trial aimed to determine which class of drug provides the best patient-rated quality of life (QoL) when used as adjuvant therapy…
- « Previous Page
- 1
- …
- 11
- 12
- 13